Found 204 clinical trials
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
refractory multiple myeloma who have received at least 3 but not more than 5 prior lines of multiple myeloma therapy.
- 186 views
- 10 May, 2022
- 28 locations
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Primary Objectives: Part 1 (dose finding, experimental substudies): -To determine or confirm the recommended dose of novel agents when combined with isatuximab with or without dexamethasone in participants with RRMM. Part 2 (expansion, experimental substudies): To demonstrate the clinical benefit of novel agents combined with isatuximab with or without dexamethasone …
- 1 views
- 27 Jul, 2022
- 17 locations
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Primary Objectives: Part 1 (dose finding, experimental substudies): -To determine or confirm the recommended dose of novel agents when combined with isatuximab with or without dexamethasone in participants with RRMM. Part 2 (expansion, experimental substudies): To demonstrate the clinical benefit of novel agents combined with isatuximab with or without dexamethasone …
- 20 views
- 05 Aug, 2022
- 19 locations
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
- 0 views
- 24 Jul, 2022
- 8 locations
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.
- 1 views
- 10 Aug, 2022
- 2 locations
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to
- 0 views
- 25 Mar, 2022
- 1 location
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at
- 1 views
- 25 Mar, 2022
- 1 location
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Evaluate the efficacy and safety of Belantamab Mafodotin, cyclophosphamide, and dexamethasone in patients with Relapsed/Refractory Multiple Myeloma
- 0 views
- 22 Mar, 2022
- 1 location
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options
- 0 views
- 23 Mar, 2022
- 1 location
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
populations of CD8+ T cells targeting multiple Myeloma associated antigen peptides in patients with relapsed refractory multiple myeloma (MM). The study will enroll patients with MM who have relapsed
- 0 views
- 27 Jan, 2021
- 4 locations